AbbVie’s Qulipta (atogepant) Receives the US FDA's Approval for Expanded Indication in Adults with Chronic Migraine
Shots:
- The approval was based on the P-III trial (PROGRESS) evaluating Qulipta (60mg, qd) vs PBO in adult patients
- The trial met its 1EPs i.e., a reduction from baseline in mean monthly migraine days across 12wk. treatment period & improvement in all six 2EPs incl. 50% reduction in mean MMDs @12wk. along with improvements in function & reduction in activity impairment due to migraine. The efficacy results were consistent with (ADVANCE) episodic migraine trial & overall safety profile was consistent with the EM patient population
- Qulipta, an oral CGRP receptor antagonist was available in the US for migraine in adults. The product is available in 10/30/60mg strengths for EM while a 60mg dose is indicated for chronic migraine patients
Ref: PRnewswire | Image: AbbVie
Related News:- AbbVie Presents P-III Study (ELEVATE) Results of Qulipta (atogepant) for the Preventive Treatment of Episodic Migraine at AAN 2023
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
